Sudden sensorineural hearing loss during pregnancy: etiology, treatment, and outcome. Issue 2 (February 2021)

• Record Type: Journal Article
• Authors: Qian, Yi; Kang, Houyong; Hu, Guohua; Zhong, Shixun; Zuo, Wenqi; Lei, Yan; Xu, Zhengyan; Chen, Tao; Zeng, Jihong
• Is Part Of: Journal of international medical research. Volume 49:Issue 2(2021)
• Publication Date: 2021-02
• Subjects: Pregnancy -- sudden sensorineural hearing loss -- intratympanic steroids -- fibrinogen -- retrospective analysis -- drug therapy; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060521990983
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To analyze the etiologies, treatments, and outcomes of sensorineural hearing loss (SSNHL) during pregnancy. Study design: Retrospective chart review of 25 pregnant patients treated for SSNHL between January 2012 and September 2019. Forty-nine age matched non-pregnant women with severe and profound hearing loss diagnosed with SSNHL during the same period served as controls. Data were recorded on age, symptoms, onset of hearing loss, audiometric results, treatments, and outcomes. Results: The mean age was 29.6 years (range 23–38 years). Intratympanic steroids (ITS) were administered in 15 (60.0%) pregnant women with SSNHL. Three women were treated with postauricular steroids only, while another woman was treated with intravenous ginkgo leaf extract and dipyridamole. The remaining six women received no medications. More than half (8/15, 53.3%) of pregnant women with SSNHL receiving ITS experienced hearing improvement. Pregnant women with profound hearing loss who received no medication had no hearing improvement. Most pregnant women with SSNHL (12/15, 80.0%) had higher fibrinogen levels than controls (mean values 3.77±0.71 g/L and 2.54±0.48 g/L, respectively). Conclusion: Fibrinogen could be a risk factor for SSNHL during pregnancy. ITS may benefit pregnant women with severe and profound SSNHL.